Hangzhou Alltest Biotech Co., Ltd. (SHA:688606)
43.61
-0.55 (-1.25%)
Nov 17, 2026, 3:00 PM CST
Hangzhou Alltest Biotech Revenue
Hangzhou Alltest Biotech had revenue of 221.08M CNY in the quarter ending September 30, 2026, with 8.78% growth. This brings the company's total for the last twelve months to 885.49M, up 0.44% year-over-year. In the year 2025, Hangzhou Alltest Biotech had annual revenue of 905.34M with 4.47% growth. That makes Hangzhou Alltest Biotech the 20,596th largest company in the world by revenue and 3,784th in China.
Revenue (ttm)
885.49M
Revenue Growth
+0.44%
P/S Ratio
3.70
Revenue / Employee
922.38K
Employees
960
Market Cap
3.27B
Revenue by Geography
- Overseas 836.44M 93.0%
- China 63.01M 7.0%
Fiscal year ended Dec 31, 2025 See the full Hangzhou Alltest Biotech breakdown
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2025 | 905.34M | 38.76M | 4.47% |
| Dec 31, 2024 | 866.58M | 111.89M | 14.83% |
| Dec 31, 2023 | 754.70M | -2.63B | -77.73% |
| Dec 31, 2022 | 3.39B | 1.52B | 80.88% |
| Dec 31, 2021 | 1.87B | 737.87M | 64.98% |
| Dec 31, 2020 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2017 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2016 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. It does not take any expenses into account and is therefore different from profits.
Related Stocks
| Company Name | Revenue |
|---|---|
| Shanghai Kindly Enterprise Development Group Co.,LTD. | 2.27B |
| Beijing Centergate Technologies (holding) | 2.06B |
| Well Lead Medical | 1.66B |
| Zhejiang Gongdong Medical Technology | 1.19B |
| Jianerkang Medical | 1.10B |
| Ningbo Tianyi Medical Appliance | 719.58M |
| Chimin Health Management | 639.18M |
| Guangzhou Jet Bio-Filtration | 590.74M |